Actinium Pharmaceuticals Inc (ATNM)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Kaushik J. Dave
Employees:
30
275 MADISON AVENUE, 7TH FLOOR, NEW YORK, NY 10016
646-677-3875

Actinium Pharmaceuticals, Inc. operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers. It targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. Its lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company was founded in 1993 and is headquartered in New York, NY.

Data derived from most recent annual or quarterly report
Market Cap 118.209 Million Shares Outstanding23.785 Million Avg 30-day Volume 163.332 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.48
Price to Revenue77.3979 Debt to Equity0.0 EBITDA-24.22 Million
Price to Book Value1.6438 Operating Margin-1693.2969 Enterprise Value40.745 Million
Current Ratio12.94 EPS Growth0.134 Quick Ratio12.584
1 Yr BETA 0.9658 52-week High/Low 10.3 / 4.41 Profit Margin-1681.4637
Operating Cash Flow Growth1.8687 Altman Z-Score6.9845 Free Cash Flow to Firm -15.32 Million
View SEC Filings from ATNM instead.

View recent insider trading info

Funds Holding ATNM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ATNM BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-29:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-13:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2021-11-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-11-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-10-28:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-14:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-05:
    Item 8.01: Other Events
  • 8-K: filed on 2020-07-24:
    Item 8.01: Other Events
  • 8-K: filed on 2020-06-19:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    STEINHART RICHARD I

    • Director
    18,351 2021-09-01 1

    SETH SANDESH CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    310,182 2021-09-01 1

    O'LOUGHLIN STEVE CHIEF FINANCIAL OFFICER

    • Officer
    107,463 2021-09-01 1

    NICHOLSON, C. DAVID

    • Director
    18,351 2021-09-01 1

    SHETTY AJIT

    • Director
    18,351 2021-09-01 1

    BERGER MARK STANLEY CHIEF MEDICAL OFFICER

    • Officer
    67,164 2021-09-01 1

    CHELL JEFFREY W.

    • Director
    18,351 2021-09-01 1

    LUDWIG DALE L. CHIEF SCIENCE & TECH. OFFICER

    • Officer
    0 2020-08-12 0

    KAPUR ANIL CHIEF COMMERCIAL OFFICER

    • Officer
    0 2019-07-12 0

    RAY NITYA G. EXECUTIVE VP

    • Officer
    0 2018-07-13 0

    DAVE KAUSHIK J CEO AND INTERIM CFO

    • Officer
    • Director
    0 2017-03-14 0

    CICIC DRAGAN CHIEF TECHNOLOGY OFFICER

    • Officer
    0 2017-03-14 0

    TRAVERSA SERGIO

    • Director
    0 2017-03-14 0

    MEMORIAL SLOAN-KETTERING CANCER CENTER

    • 10% Owner
    No longer subject to file 2016-08-30 0

    MEMORIAL SLOAN-KETTERING CANCER CENTER

    AHLB HOLDINGS, LLC

    ACTINIUM HOLDINGS, LTD.

    • 10% Owner
    5,702,387 2015-05-06 0

    MAZANET ROSEMARY

    • Director
    100 2013-05-15 0

    BUTTON DIANE S PRESIDENT/SECRETARY/TREASURER

    • Officer
    • Director
    20,000,000 2007-02-07 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 22:15:03 UTC -0.7384 2.3084 650000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 21:45:03 UTC -0.7384 2.3084 650000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 21:15:03 UTC -0.7384 2.3084 650000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 20:45:03 UTC -0.7384 2.3084 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 20:15:04 UTC -0.7384 2.3084 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 19:45:03 UTC -0.7384 2.3084 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 19:15:03 UTC -0.7384 2.3084 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 18:45:04 UTC -0.7449 2.3149 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 18:15:04 UTC -0.7449 2.3149 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 17:45:03 UTC -0.7449 2.3149 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 17:15:03 UTC -0.7449 2.3149 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 16:45:04 UTC -0.9886 2.5586 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 16:15:03 UTC -0.9886 2.5586 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 15:45:03 UTC -0.9886 2.5586 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 15:15:03 UTC -0.9886 2.5586 700000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 14:45:03 UTC -0.9886 2.5586 750000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 14:15:03 UTC -0.9886 2.5586 750000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 13:45:03 UTC -0.9886 2.5586 750000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 13:15:03 UTC -0.9886 2.5586 750000
    ACTINIUM PHARMACEUTICALS INC ATNM 2022-06-30 12:45:03 UTC -0.9886 2.5586 750000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ATNM -2686.0 shares, $-13725.46 2022-03-31 N-PORT

    Elevate your investments